Table 1.
Patient demographics and clinical characteristics
| Characteristic | ATL patients (n = 14) | PTCL patients (n = 11) | |||
|---|---|---|---|---|---|
| n (%) | n (%) | ||||
| Age (years) | Median | 56 | 69 | ||
| Range | 47–72 | 36–78 | |||
| Sex | Male | 9 (64) | 9 (82) | ||
| Female | 5 (36) | 2 (18) | |||
| ECOG PS | 0 | 2 (14) | 5 (45) | ||
| 1 | 9 (64) | 4 (36) | |||
| 2 | 2 (14) | 2 (18) | |||
| 3 | 0 (0) | 0 (0) | |||
| 4 | 1 (7) | 0 (0) | |||
| Therapy | CHOP/-L | 5 (36) | 11 (100) | ||
| mLSG15/-L | 9 (64) | 0 (0) | |||
| Subtype | Acute | 10 (71) | AITL | 5 (45) | |
| Lymphoma | 1 (7) | PTCL-NOS | 3 (27) | ||
| Chronic | 3 (21) | ALCL ALK- | 1 (9) | ||
| EATL | 1 (9) | ||||
| SPTCL | 1 (9) | ||||
AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, ATL adult T-cell leukemia–lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP/-L CHOP or CHOP-like regimen, EATL enteropathy-associated T-cell lymphoma, ECOG Eastern Cooperative Oncology Group, mLSG15 vincristine, cyclophosphamide, doxorubicin, prednisone and doxorubicin, ranimustine, prednisone and vindesine, etoposide, carboplatin, prednisone, mLSG15/-L mLSG15 or mLSG15-like regimen, NOS not otherwise specified, PS performance status, PTCL peripheral T-cell lymphoma, SPTCL subcutaneous panniculitis-like T-cell lymphoma